The research and development process, market price and drug purchase advice of osimertinib (osimertinib)

Osimertinib, also known as osimertinib, its trade name is Tagrisso/AZD9291/TAGRISSO, is a third-generation EGFR tyrosine kinase inhibitor (TKI) developed by AstraZeneca. This drug was developed mainly to solve the problem of treatment resistance caused by EGFR mutations in patients with non-small cell lung cancer (NSCLC). EGFR mutations are common driver gene mutations in NSCLC, and resistance to first- and second-generation EGFR TKIs often occurs during treatment, especially the EGFR T790M mutation. The emergence of osimertinib provides patients with a new treatment strategy that can precisely target EGFR sensitive mutations and EGFR T790M mutations.

As osimertinib is widely used and recognized around the world, the high price of its original drug has also become a burden for many patients. For this reason, a variety of generic drugs of osimertinib have emerged on the market, with more affordable prices. At the same time, these generic drugs follow international standards in terms of manufacturing process and quality, ensuring their reliable quality. Different versions of generic drugs vary in price, providing patients with more choices.

For patients who plan to purchase osimertinib, there are several key drug purchase recommendations worth referring to. First of all, it is important to choose formal drug purchasing channels, such as regular hospitals, pharmacies or authorized overseas medical service institutions. These channels can ensure the quality of medicines and provide necessary after-sales support. Secondly, be sure to verify the approval number, manufacturer, expiry date and other information of the drug before purchasing to ensure that you are purchasing real and effective drugs. In addition, the transportation and storage conditions of drugs cannot be ignored to ensure that the drugs maintain their original efficacy before reaching the patients.

When using osimertinib, patients should strictly follow the doctor's instructions, ensure regular and quantitative use, and pay attention to possible side effects. If you have any discomfort, you should communicate with your doctor immediately and adjust the treatment plan.

In summary, osimertinib, as an innovativeEGFR TKI drug, brings new treatment hope to NSCLC patients. Although the original drugs are expensive, generic drugs on the market provide patients with more economical treatment options. During the purchase and use of medicines, patients should remain cautious, choose formal channels and follow medical instructions to ensure the safety and effectiveness of treatment.